Trials

CORRECTION

Open Access

# Correction: End-ischemic hypothermic oxygenated perfusion for extended criteria donors in liver transplantation: a multicenter, randomized controlled trial—HOPExt

Pierre Pradat[1*], Solene Pantel[1], Marianne Maynard[1], Laure Lalande[2], Sylvie Thevenon[1], Rene Adam[3], Marc-Antoine Allard[3], Fabien Robin[4], Michel Rayar[4], Emmanuel Boleslawski[5], Olivier Scatton[6], Mircea Chirica[7], François Faitot[8], Philippe Bachellier[8], Olivier Soubrane[9], Kayvan Mohkam[10], Jean-Yves Mabrut[10†] and Mickaël Lesurtel[10†]

Correction: BMC Trials 24, 379 (2023)
**https://doi.org/10.1186/s13063-023-07402-0**

Following publication of the original article [1], we have been informed that Table 1 has been misaligned during typesetting.

The original article has been corrected.

†Jean-Yves Mabrut and Mickaël Lesurtel share the senior author position.

The original article can be found online at https://doi.org/10.1186/s13063-023-07402-0.

*Correspondence:
Pierre Pradat
pierre.pradat@univ-lyon1.fr
[1] Centre for Clinical Research, Hospices Civils de Lyon, Croix-Rousse University Hospital, Lyon, France
[2] Department of Pharmacy, Croix-Rousse University Hospital, Hospices Civils de Lyon, Lyon, France
[3] Department of HPB Surgery and Liver Transplantation, Paul Brousse University Hospital, Villejuif, France
[4] Department of HPB Surgery and Liver Transplantation, Pontchaillou Univer- Sity Hospital, Rennes, France
[5] Department of HPB Surgery and Liver Transplan- Tation, Claude Huriez University Hospital, Lille, France
[6] Department of HPB Surgery and Liver Transplantation, Pitié Salpêtrière Hospital, Paris, France
[7] Department of HPB Surgery and Liver Transplantation, Michallon University Hospital, Grenoble, France
[8] Department of HPB Surgery and Liver Transplanta- Tion, Hautepierre University Hospital, Strasbourg, France
[9] Department of HPB Surgery and Liver Transplantation, Beaujon University Hospital, Clichy, France
[10] Department of Digestive Surgery and Liver Transplantation, Croix-Rousse University Hospital, Hospices Civils de Lyon, Lyon, France

**Table 1** Schedule of enrolment, interventions, and assessments in the HOPExt trial

| ***STAGES*** | ***V1*** **Screening** | ***V2*** **Inclusion** | | ***V3*** | ***V4*** | ***V5 –V11*** | ***V12*** | ***V13-V16*** |
|---|---|---|---|---|---|---|---|---|
| ***Time point*** Actions | ***At inscription for LT or at pre LT visit*** | ***D0 At hospitalization for LT*** | ***D0*** HOPE group only | ***D0 + 6 h (± 2 h) after LT*** | ***D0 + 12 h (± 2 h)*** after LT | ***Day 1 to day 7 (± 1 day)*** | ***End of hospital stay*** | ***M3; M6: M9 and M12 (± 30 days)*** |
| ***Inclusion / non-inclusion criteria*** | *X* | *X* | | | | | | |
| ***Informed consent*** | *X* | | | | | | | |
| ***Medical history and patient characteristics***[1] | *X* | | | | | | | |
| ***MELD score*** | *X At inscription* | *X* | | | | | | |
| ***Randomization***[2] | | *X* | | | | | | |
| ***Clinical examination***[3] | | *X* | | | | | *X* | *X* |
| ***Biological analyses***[4] | | *X* *(before LT)* | | *X* | *X* | *X* | *X* | *X* |
| ***CHILD–PUGH score*** | | *X* *(before LT)* | | | | | | |
| ***Donor characteristics***[5] | | *X* | | | | | | |
| ***HOPE perfusion parameters***[6] | | | *X* | | | | | |
| ***Bacteriological and fungal analyses***[7] | | *X* | *X* | | | | | |
| ***Intra-operative data***[8] | | *X* | | | | | | |
| ***Liver Biopsy***[9] | | *X* *both groups* | *X* | | | | | |
| ***Machine perfusate sample***[10] | | | *X* | | | | | |
| *ICU and hospital stay* | | | | | | | *X* | |
| ***Morbidity (Clavien-Dindo Score, CCI)*** | | | | | | | *X* | *X* *At M3 only* |
| ***Concomitant Medication*** | | *X* | | *X* | *X* | *X* | *X* | *X* |
| ***Adverse events*** | | *X* | | *X* | *X* | *X* | *X* | *X* |
| ***Abdominal contrast enhanced MRI/MRCP*** | | | | | | | | *X* *At M12 only* |

[1] patient characteristics: age, gender, height, weight, BMI, blood group, cause of cirrhosis, indication for transplantation, medical history (diabetes mellitus, arterial hypertension, transjugular intrahepatic portosystemic shunt) pretransplant status of residence (home, hospital ward or intensive care unit (ICU))

[2] Randomization will be performed after the harvesting team has macroscopically assessed the graft and confirmed that the graft will be harvested. After checking the inclusion and non-inclusion criteria an online randomization tool will be used. Randomization will be stratified by center and MELD score at the time of transplantation with a cut-off of 30

[3] Clinical examination: vital signs (temperature, blood pressure, heart rate), body weight, height, BMI

[4] Biological analyses: AST, ALT, GGT, Alkaline Phosphatase, bilirubin, factor V, INR, platelets, creatinine, GFR, lactates

At V2 only, a pregnancy test (beta HCG) will be done for women of childbearing age

[5] Donor characteristics**:** age, gender, height, weight, BMI, blood group, length of stay in intensive care unit, cause of death, occurrence of cardiac arrest, biological test (AST, ALT, natremia)

[6] Parameters measured during HOPE perfusion (only in HOPE group): perfusion pressure, flow, temperature, duration of machine perfusion, perfusate oxygenation (partial pressure O2) and CO2 content (partial pressure CO2) at the beginning and at the end of machine perfusion; perfusate AST and ALT, LDH, hyaluronic acid, lactate levels at 30 minutes and at the end of machine perfusion

[7] Bacteriological and fungal samplings will be taken on static storage solution (IGL-1) at the end of the back-table in both groups, and of the perfusion solution at the end of machine perfusion for HOPE group

[8] Intra-operative data: surgical technique of transplantation (piggy-back vs. vena cava resection), length of procedure, transfusion needs (fresh frozen plasma, red blood cell, thrombocyte concentrate), occurrence of post-reperfusion syndrome (decrease of 50% of the median arterial pressure during the 5 minutes after the revascularisation), cold ischemia time, circulatory support at the end of transplantation (noradrenaline (mg/h))

[9] A biopsy will be taken on the back-table before machine perfusion in both study groups, immediately after liver machine perfusion in the HOPE group, and after reperfusion of the liver in both groups

[10] 3ml sample will be taken from machine perfusion solution during HOPE perfusion (only in HOPE group), at 30 minutes and at the end of machine perfusion

Published online: 14 August 2023

## Reference

1. Pradat Pierre, et al. End-ischemic hypothermic oxygenated perfusion for extended criteria donors in liver transplantation: a multicenter, randomized controlled trial—HOPExt. BMC Trials. 2023;24:379. https://doi.org/10.1186/s13063-023-07402-0.